AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25976046
Drug: Blood glucose
RxNorm normalized name: Blood Glucose Book
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood glucose levels of 4.4 to 6.1 mmol/L (Group A)
Trial: 25976046
Drug: Blood glucose
RxNorm normalized name: Blood Glucose Book
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood glucose levels of 6.1 to 8.3 mmol/L (Group B)
Trial: 25976046
Drug: Blood glucose
RxNorm normalized name: Blood Glucose Book
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood glucose levels of 8.3 to 10.0 mmol/L (Group C)
Trial: 18836440
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin or norepinephrine re‐uptake inhibitors after training
Trial: 7957836
Drug: Nebulized frusemide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized frusemide (40 mg)
Trial: 3602414
Drug: Amineptine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amineptine treatment
Trial: 31230500
Drug: Nonwarfarin oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonwarfarin oral anticoagulants (NOACs)
Trial: 28623954
Drug: Alirocumab 150
RxNorm normalized name: alirocumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 150 mg SC Q4W
Trial: 28623954
Drug: Alirocumab 150
RxNorm normalized name: alirocumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 150 mg SC Q2W
Trial: 23391342
Drug: Clonidine150 (Bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine150 (Bupivacaine 0.5% + 150 μg of clonidine)
Trial: 23391342
Drug: Clonidine250 (Bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine250 (Bupivacaine 0.5% + 250 μg of clonidine)
Trial: 11986408
Drug: Etanercept (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (25 mg, twice-weekly subcutaneous injections)
Trial: 7619892
Drug: CGS 13429A
RxNorm normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGS 13429A (0.1 to 10 mg)
Trial: 2196520
Drug: Methylphenidate 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate 0.3 mg/kg twice a day
Trial: 2196520
Drug: Methylphenidate 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate 0.5 mg/kg twice a day
Trial: 24640648
Drug: Statokinesitherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statokinesitherapy with biological feedback
Trial: 21228334
Drug: Lenalidomide 25
RxNorm normalized name: lenalidomide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 25 mg orally on days 1-21 every 28 days until progression or as tolerated
Trial: 17030175
Drug: Oral norfloxacin
RxNorm normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral norfloxacin (400 mg twice daily)
Trial: 17030175
Drug: Intravenous ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ceftriaxone (1 g/day)
Trial: 12575375
Drug: Qidan Tongmai
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Qidan Tongmai tablet (QDTMT) in Group A (33 cases without HLC)
Trial: 12575375
Drug: Qidan Tongmai
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Qidan Tongmai tablet (QDTMT) in Group B (33 cases with HLC)
Trial: 3576521
Drug: Aspirin 10
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 10 mg daily for 3 weeks
Trial: 3576521
Drug: Aspirin 30
RxNorm normalized name: aspirin 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 30 mg daily for 3 weeks
Trial: 3576521
Drug: Aspirin 10
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 10 mg and 30 mg
Trial: 28467150
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (120 mg via nasogastric tube for 15 days)
Trial: 27225859
Drug: 0.005 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.005 mg/kg glycopyrrolate
Trial: 24856612
Drug: Once-daily glargine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily glargine
Trial: 22747603
Drug: Chlorhexidine gel
RxNorm normalized name: chlorhexidine Oral Gel
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine gel (CHX-gel) (5.0%)
Trial: 22747603
Drug: Octenidine gel
RxNorm normalized name: octenidine
DrugBank: Octenidine (DB12624)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octenidine gel (OCT-gel) (5.0%)
Trial: 16927283
Drug: Pegylated interferon-alpha
RxNorm normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon-alpha plus ribavirin (treatment for persistent HCV infection)
Trial: 8479129
Drug: Antioxidant therapy
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant therapy with two ampoules of Omnibionta (vitamins C, E, A, and B complex) diluted in 500 ml physiological sodium chloride, infused intravenously prior to reperfusion onset.
Trial: 8479129
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no antioxidant therapy).
Trial: 8479129
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between therapy and control groups one hour after reperfusion.
Trial: 3310159
Drug: Theophylline (TH;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (TH; 234 mg)
Trial: 3310159
Drug: Neo-Biphyllin (NB;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neo-Biphyllin (NB; 600 mg)
Trial: 25995322
Drug: Sildenafil 20
RxNorm normalized name: sildenafil 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 20 mg, three times daily for 12 weeks
Trial: 24742755
Drug: Contextual factor:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contextual factor: treatment study phase
Trial: 23319574
Drug: Pomalidomide (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomalidomide (4 mg) on days 1 to 21 (arm 21/28) plus weekly dexamethasone
Trial: 23319574
Drug: Pomalidomide (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomalidomide (4 mg) continuously (arm 28/28) plus weekly dexamethasone
Trial: 19961914
Drug: Chios mastic
RxNorm normalized name: Thymus mastichina flowering top oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chios mastic gum 350 mg three times daily
Trial: 17340612
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment (CBT) group
Trial: 15206735
Drug: Tryptophan (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tryptophan (1 g after each meal for 12 days)
Trial: 10339997
Drug: Caudal epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal epidural injection of 1 ml (7 mg) bethametason in 10 ml normal saline and 20 ml local anesthetic (Lignocaine 1%)
Trial: 10339997
Drug: Caudal epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal epidural injection of 20 ml local anaesthetic (Lignocaine 1%) and 10 ml normal saline
Trial: 10339997
Drug: Superficial injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Superficial injection of 1 ml (7 mg) bethametason around the sacral hiatus
Trial: 7676778
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg 0.5% bupivacaine
Trial: 7676778
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg 0.5% bupivacaine
Trial: 7676778
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (25 mg and 30 mg)
Trial: 31027084
Drug: Prolonged anticoagulation
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged anticoagulation therapy (median duration: 72.6 hours)
Trial: 31027084
Drug: Brief anticoagulation
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief anticoagulation therapy (median duration: 5 hours)
Trial: 31027084
Drug: Prolonged anticoagulation
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged anticoagulation therapy
Trial: 31027084
Drug: Brief anticoagulation
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief anticoagulation therapy
Trial: 28110155
Drug: RO5046013 (PEGylated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO5046013 (PEGylated recombinant human insulin-like growth factor-I)
Trial: 28110155
Drug: rhIGF‐I (unmodified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIGF‐I (unmodified recombinant human insulin-like growth factor-I)
Trial: 26499007
Drug: Drotaverine hydrochloride
RxNorm normalized name: drotaverine hydrochloride
DrugBank: Drotaverine (DB06751)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drotaverine hydrochloride (20 mg syrup for ages 4-6, 40 mg tablet for ages >6)
Trial: 19621678
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of two mononucleotide markers (BAT26 and BAT25)
Trial: 15579778
Drug: Prednisone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (0.5 mg/kg.d)
Trial: 8431411
Drug: Arthroscopic surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthroscopic surgery followed by post-operative physical therapy (n = 9)
Trial: 8431411
Drug: Non-surgical treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical treatment (n = 12)
Trial: 3608730
Drug: Loperamide (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide (16 mg per os)
Trial: 3608730
Drug: Loperamide (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide (16 mg per os) followed by naloxone (16 mg)
Trial: 3608730
Drug: Loperamide (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide (16 mg per os) followed by naloxone (32 mg)
Trial: 29310611
Drug: Oxaliplatin +
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin + S-1 (oxaliplatin dose of 130 mg/m2)
Trial: 21129714
Drug: Bisoprolol (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol (1.25 mg once daily)
Trial: 21129714
Drug: Carvedilol (3.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (3.125 mg twice daily)
Trial: 18353086
Drug: Surface preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surface preparation (gentle curettage or abrasion with a spatula)
Trial: 15080820
Drug: Butterbur (BB)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butterbur (BB) 50 mg twice daily
Trial: 1812440
Drug: Norwegian meningococcus
RxNorm normalized name: MENINGOCOCCAL B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norwegian meningococcus B vaccine
Trial: 26731173
Drug: Therapist-guided internet-delivered
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist-guided internet-delivered acceptance-based behaviour therapy
Trial: 2529892
Drug: Tamoxifen 20
RxNorm normalized name: tamoxifen 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 20 mg b.d.
Trial: 2529892
Drug: Cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate 100 mg t.d.s.
Trial: 4692674
Drug: Hibiscrub (4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hibiscrub (4% chlorhexidine detergent solution)
Trial: 4692674
Drug: Dermofax (0.75%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dermofax (0.75% chlorhexidine detergent solution)
Trial: 4692674
Drug: Disadine scrub
RxNorm normalized name: Scrub-Stat
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Disadine scrub (povidone iodine detergent preparation)
Trial: 4692674
Drug: Hibiscrub (4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hibiscrub (4% chlorhexidine detergent solution) after six applications
Trial: 4692674
Drug: Dermofax (0.75%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dermofax (0.75% chlorhexidine detergent solution) after six applications
Trial: 24698702
Drug: Wet-wrap treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wet-wrap treatment (WWT) with diluted corticosteroids (1:3 mometasone furoate 0.1% ointment and for the face 1:19 mometasone furoate 0.1% ointment under a mask)
Trial: 24698702
Drug: Emollient (petrolatum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emollient (petrolatum 20% in cetomacrogol cream)
Trial: 24698702
Drug: Wet-wrap treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wet-wrap treatment (WWT) with diluted corticosteroids
Trial: 23588625
Drug: L-Cat intervention
RxNorm normalized name: cat hair extract
DrugBank: Felis catus hair (DB10499)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Cat intervention
Trial: 20716244
Drug: Concomitant ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Concomitant ibuprofen and paracetamol
Trial: 18069745
Drug: Chemotherapy added
RxNorm normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy added to locoregional treatment
Trial: 16360564
Drug: Electronic survey
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic survey (tablet)
Trial: 12846755
Drug: rhIGF-1 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIGF-1 (100 mg/kg subcutaneously twice a day for 6 days)
Trial: 11158455
Drug: Cholesterol-lowering dietary
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholesterol-lowering dietary intervention promoting adherence to a diet with 28% of energy from total fat, <8% from saturated fat, up to 9% from polyunsaturated fat, and <75 mg/1000 kcal cholesterol per day
Trial: 9047258
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose chemotherapy followed by infusion of autologous hematopoietic stem cells and growth factors
Trial: 9047258
Drug: Standard adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard adjuvant therapies
Trial: 3036259
Drug: Metergoline 4
RxNorm normalized name: metergoline 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metergoline 4 mg
Trial: 2102029
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg allopurinol + 20 mg benzbromarone
Trial: 2102029
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg allopurinol only
Trial: 28898714
Drug: Continued care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued care (CC) with weekly to monthly phone calls from a diabetes specialist nurse practitioner
Trial: 28898714
Drug: Continued care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued care (CC) for insulin-treated patients
Trial: 28898714
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (UC) for insulin-treated patients
Trial: 17432641
Drug: Triamcinolone and
RxNorm normalized name: triamcinolone and antiseptics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triamcinolone and urea cream
Trial: 9972900
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no FGF injection).
Trial: 7919075
Drug: Nurse-administered health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-administered health checks
Trial: 29642075
Drug: Topical sucralfate
RxNorm normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical sucralfate gel
Trial: 25178692
Drug: Intravenous amiodarone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous amiodarone (300 mg loading dose followed by 15 mg/kg infusion for two days)
Trial: 23565591
Drug: Intensive advice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive advice to withdraw overused medication (Group A)
Trial: 10743865
Drug: No gel
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No gel (control)
Trial: 1460163
Drug: ECT, fluoxetine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECT, fluoxetine, or amitriptyline
Trial: 6229740
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g metronidazole suppository, administered 12-hourly starting 48 hours before elective surgery
Trial: 6229740
Drug: 0.5 g
RxNorm normalized name: Gelatin Capsules, 10.5 gr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g metronidazole i.v. over 20 minutes and 1 g suppository at premedication, continued with one suppository 12-hourly
Trial: 6229740
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g metronidazole suppository, administered 8-hourly starting 24 hours before surgery for high-risk patients
Trial: 6229740
Drug: Rectal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal treatment
Trial: 30650291
Drug: Longbishu Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longbishu Capsule (LBS) placebos combined Doxazosin Mesylate Tablet (DMT)
Trial: 30650291
Drug: Longbishu Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longbishu Capsule (LBS) combined Doxazosin Mesylate Tablet (DMT)
Trial: 30650291
Drug: Longbishu Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longbishu Capsule (LBS) combined Doxazosin Mesylate Tablet (DMT) placebos
Trial: 24746224
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (BVA + NSAIDs)
Trial: 23172029
Drug: lidocaine/prilocaine cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lidocaine/prilocaine cream
Trial: 23172029
Drug: 10 mM
RxNorm normalized name: potassium 10 MMOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mM N(G)‐monomethyl‐l‐arginine (l‐NMMA)
Trial: 23172029
Drug: fluconazole +
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: fluconazole + l‐NMMA
Trial: 15878759
Drug: Accelerated chemotherapy
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated chemotherapy (CT) regimen: 3 cycles of cisplatin and 5-fluorouracil (days 1, 14, and 28) followed by hyperfractionated radiation therapy (RT) (7440 cGy/62 fractions)
Trial: 12560354
Drug: 400 microg
RxNorm normalized name: Fentanyl 400 microgram buccal film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 microg folic acid supplement plus natural diet
Trial: 10622750
Drug: 100 mL
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL of 25% albumin
Trial: 7791169
Drug: Indomethacin 150
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin 150 mg/day (Group A)
Trial: 7791169
Drug: Indomethacin 150
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin 150 mg/day plus misoprostol at 0.6 mg/day (Group B)
Trial: 2289220
Drug: Tulobuterol 40
RxNorm normalized name: tulobuterol
DrugBank: Tulobuterol (DB12248)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tulobuterol 40 micrograms/kg twice daily
Trial: 2289220
Drug: Albuterol 100
RxNorm normalized name: ALBUTEROL 100/IPRATRO 20MCG 120D PO INHL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol 100 micrograms/kg three times daily
Trial: 7235865
Drug: Postoperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative chemotherapy (B group)
Trial: 7235865
Drug: No follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No follow-up treatment (A group)
Trial: 28051319
Drug: Yoga program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga program (12 weeks, twice a week for 60 minutes, including breathing exercises, yoga pose practice, and supine meditation/relaxation)
Trial: 26301241
Drug: Signature CT-based
RxNorm normalized name: Ct-053 free base
DrugBank: Ningetinib (DB16256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Signature CT-based implant positioning system
Trial: 21372621
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) and Well-Being Therapy (WBT)
Trial: 17133051
Drug: Medication (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (n = 19)
Trial: 17133051
Drug: Medication (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (n = 26)
Trial: 10972631
Drug: Immediate simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate simvastatin treatment (40 mg/d)